Publications

Detailed Information

Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer

DC Field Value Language
dc.contributor.authorShitara, Kohei-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorIwasa, Satoru-
dc.contributor.authorSugimoto, Naotoshi-
dc.contributor.authorRyu, Min-Hee-
dc.contributor.authorSakai, Daisuke-
dc.contributor.authorChung, Hyun-Cheol-
dc.contributor.authorKawakami, Hisato-
dc.contributor.authorYabusaki, Hiroshi-
dc.contributor.authorLee, Jeeyun-
dc.contributor.authorSaito, Kaku-
dc.contributor.authorKawaguchi, Yoshinori-
dc.contributor.authorKamio, Takahiro-
dc.contributor.authorKojima, Akihito-
dc.contributor.authorSugihara, Masahiro-
dc.contributor.authorYamaguchi, Kensei-
dc.date.accessioned2021-01-31T12:04:28Z-
dc.date.available2021-01-31T12:04:28Z-
dc.date.created2020-07-20-
dc.date.created2020-07-20-
dc.date.issued2020-06-
dc.identifier.citationNew England Journal of Medicine, Vol.382 No.25, pp.2419-2430-
dc.identifier.issn0028-4793-
dc.identifier.other107472-
dc.identifier.urihttps://hdl.handle.net/10371/173254-
dc.description.abstractBackground Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. The drug may have efficacy in patients with HER2-positive advanced gastric cancer. Methods In an open-label, randomized, phase 2 trial, we evaluated trastuzumab deruxtecan as compared with chemotherapy in patients with HER2-positive advanced gastric cancer. Patients with centrally confirmed HER2-positive gastric or gastroesophageal junction adenocarcinoma that had progressed while they were receiving at least two previous therapies, including trastuzumab, were randomly assigned in a 2:1 ratio to receive trastuzumab deruxtecan (6.4 mg per kilogram of body weight every 3 weeks) or physician's choice of chemotherapy. The primary end point was the objective response, according to independent central review. Secondary end points included overall survival, response duration, progression-free survival, confirmed response (response persisting >= 4 weeks), and safety. Results Of 187 treated patients, 125 received trastuzumab deruxtecan and 62 chemotherapy (55 received irinotecan and 7 paclitaxel). An objective response was reported in 51% of the patients in the trastuzumab deruxtecan group, as compared with 14% of those in the physician's choice group (P<0.001). Overall survival was longer with trastuzumab deruxtecan than with chemotherapy (median, 12.5 vs. 8.4 months; hazard ratio for death, 0.59; 95% confidence interval, 0.39 to 0.88; P=0.01, which crossed the prespecified O'Brien-Fleming boundary [0.0202 on the basis of number of deaths]). The most common adverse events of grade 3 or higher were a decreased neutrophil count (in 51% of the trastuzumab deruxtecan group and 24% of the physician's choice group), anemia (38% and 23%, respectively), and decreased white-cell count (21% and 11%). A total of 12 patients had trastuzumab deruxtecan-related interstitial lung disease or pneumonitis (grade 1 or 2 in 9 patients and grade 3 or 4 in 3), as adjudicated by an independent committee. One drug-related death (due to pneumonia) was noted in the trastuzumab deruxtecan group; no drug-related deaths occurred in the physician's choice group. Conclusions Therapy with trastuzumab deruxtecan led to significant improvements in response and overall survival, as compared with standard therapies, among patients with HER2-positive gastric cancer. Myelosuppression and interstitial lung disease were the notable toxic effects. (Funded by Daiichi Sankyo; DESTINY-Gastric01 ClinicalTrials.gov number,.) Approximately 15 to 20% of gastric adenocarcinomas express HER2. Trastuzumab deruxtecan is an antibody-drug conjugate composed of trastuzumab and the topoisomerase I inhibitor deruxtecan. In a randomized trial, the antibody-drug conjugate led to higher response and longer overall survival than physician's choice of therapy among patients with relapsed disease.-
dc.language영어-
dc.publisherMassachusetts Medical Society-
dc.titleTrastuzumab deruxtecan in previously treated HER2-positive gastric cancer-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1056/NEJMoa2004413-
dc.citation.journaltitleNew England Journal of Medicine-
dc.identifier.wosid000545644400007-
dc.identifier.scopusid2-s2.0-85086332066-
dc.citation.endpage2430-
dc.citation.number25-
dc.citation.startpage2419-
dc.citation.volume382-
dc.identifier.sci000545644400007-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusDOUBLE-BLIND-
dc.subject.keywordPlusPLUS PACLITAXEL-
dc.subject.keywordPlusCATHEPSIN-B-
dc.subject.keywordPlusHER2-
dc.subject.keywordPlusEMTANSINE-
dc.subject.keywordPlusTHERAPY-
dc.subject.keywordPlusCHEMOTHERAPY-
dc.subject.keywordPlusPERTUZUMAB-
dc.subject.keywordPlusDOCETAXEL-
dc.subject.keywordPlusLAPATINIB-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share